Trial
NCT02446652
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
Phase IIIWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
National Institute of Cancerología
Collaborators
Psicofarma, S.A. De C.V.
Condition
Cervical Cancer
Intervention
Hydralazine/Magnesium
Why stopped
Due to a lack of sufficient resources, the opening was not carried out.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-29